Skip to main content
Top
Published in: Head & Face Medicine 1/2009

Open Access 01-12-2009 | Research

Biological activity of a genetically modified BMP-2 variant with inhibitory activity

Authors: Uwe Klammert, Joachim Nickel, Kristian Würzler, Christoph Klingelhöffer, Walter Sebald, Alexander C Kübler, Tobias Reuther

Published in: Head & Face Medicine | Issue 1/2009

Login to get access

Abstract

Background

Alterations of the binding epitopes of bone morphogenetic protein-2 (BMP-2) lead to a modified interaction with the ectodomains of BMP receptors. In the present study the biological effect of a BMP-2 double mutant with antagonistic activity was evaluated in vivo.

Methods

Equine-derived collagenous carriers were loaded with recombinant human BMP-2 (rhBMP-2) in a well-known dose to provide an osteoinductive stimulus. The study was performed in a split animal design: carriers only coupled with rhBMP-2 (control) were implanted into prepared cavities of lower limb muscle of rats, specimens coupled with rhBMP-2 as well as BMP-2 double mutant were placed into the opposite limb in the same way. After 28 days the carriers were explanted, measured radiographically and characterized histologically.

Results

As expected, the BMP-2 loaded implants showed a typical heterotopic bone formation. The specimens coupled with both proteins showed a significant decreased bone formation in a dose dependent manner.

Conclusion

The antagonistic effect of a specific BMP-2 double mutant could be demonstrated in vivo. The dose dependent influence on heterotopic bone formation by preventing rhBMP-2 induced osteoinduction suggests a competitive receptor antagonism.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wang XL, Malghem J, Parizel PM, Gielen JL, Vanhoenacker F, De Schepper AM: Pictorial essay. Myositis ossificans circumscripta. JBR-BTR. 2003, 86: 278-285.PubMed Wang XL, Malghem J, Parizel PM, Gielen JL, Vanhoenacker F, De Schepper AM: Pictorial essay. Myositis ossificans circumscripta. JBR-BTR. 2003, 86: 278-285.PubMed
2.
go back to reference Smith R: Fibrodysplasia (myositis) ossificans progressiva. Clinical lessons from a rare disease. Clin Orthop Relat Res. 1998, 346: 7-14. 10.1097/00003086-199801000-00003.CrossRefPubMed Smith R: Fibrodysplasia (myositis) ossificans progressiva. Clinical lessons from a rare disease. Clin Orthop Relat Res. 1998, 346: 7-14. 10.1097/00003086-199801000-00003.CrossRefPubMed
3.
go back to reference Kaplan FS, Glaser DL, Hebela N, Shore EM: Heterotopic ossification. J Am Acad Orthop Surg. 2004, 12: 116-125.CrossRefPubMed Kaplan FS, Glaser DL, Hebela N, Shore EM: Heterotopic ossification. J Am Acad Orthop Surg. 2004, 12: 116-125.CrossRefPubMed
4.
go back to reference Luchetti W, Cohen RB, Hahn GV, Rocke DM, Helpin M, Zasloff M, Kaplan FS: Severe restriction in jaw movement after routine injection of local anesthetic in patients who have fibrodysplasia ossificans progressiva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996, 81: 21-25. 10.1016/S1079-2104(96)80141-7.CrossRefPubMed Luchetti W, Cohen RB, Hahn GV, Rocke DM, Helpin M, Zasloff M, Kaplan FS: Severe restriction in jaw movement after routine injection of local anesthetic in patients who have fibrodysplasia ossificans progressiva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996, 81: 21-25. 10.1016/S1079-2104(96)80141-7.CrossRefPubMed
5.
go back to reference Olmsted EA, Kaplan FS, Shore EM: Bone morphogenetic protein-4 regulation in fibrodysplasia ossificans progressiva. Clin Orthop Relat Res. 2003, 408: 331-343. 10.1097/00003086-200303000-00044.CrossRefPubMed Olmsted EA, Kaplan FS, Shore EM: Bone morphogenetic protein-4 regulation in fibrodysplasia ossificans progressiva. Clin Orthop Relat Res. 2003, 408: 331-343. 10.1097/00003086-200303000-00044.CrossRefPubMed
6.
go back to reference Ahn J, Serrano de la Pena L, Shore EM, Kaplan FS: Paresis of a bone morphogenetic protein-antagonist response in a genetic disorder of heterotopic skeletogenesis. J Bone Joint Surg Am. 2003, 85-A: 667-674.PubMed Ahn J, Serrano de la Pena L, Shore EM, Kaplan FS: Paresis of a bone morphogenetic protein-antagonist response in a genetic disorder of heterotopic skeletogenesis. J Bone Joint Surg Am. 2003, 85-A: 667-674.PubMed
7.
go back to reference Shafritz AB, Shore EM, Gannon FH, Zasloff MA, Taub R, Muenke M, Kaplan FS: Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. N Engl J Med. 1996, 335: 555-561. 10.1056/NEJM199608223350804.CrossRefPubMed Shafritz AB, Shore EM, Gannon FH, Zasloff MA, Taub R, Muenke M, Kaplan FS: Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. N Engl J Med. 1996, 335: 555-561. 10.1056/NEJM199608223350804.CrossRefPubMed
8.
go back to reference Feldman G, Li M, Martin S, Urbanek M, Urtizberea JA, Fardeau M, LeMerrer M, Connor JM, Triffitt J, Smith R, Muenke M, Kaplan FS, Shore EM: Fibrodysplasia ossificans progressiva, a heritable disorder of severe heterotopic ossification, maps to human chromosome 4q27-31. Am J Hum Genet. 2000, 66: 128-135. 10.1086/302724.CrossRefPubMed Feldman G, Li M, Martin S, Urbanek M, Urtizberea JA, Fardeau M, LeMerrer M, Connor JM, Triffitt J, Smith R, Muenke M, Kaplan FS, Shore EM: Fibrodysplasia ossificans progressiva, a heritable disorder of severe heterotopic ossification, maps to human chromosome 4q27-31. Am J Hum Genet. 2000, 66: 128-135. 10.1086/302724.CrossRefPubMed
9.
go back to reference Massague J: TGF-beta signal transduction. Annu Rev Biochem. 1998, 67: 753-791. 10.1146/annurev.biochem.67.1.753.CrossRefPubMed Massague J: TGF-beta signal transduction. Annu Rev Biochem. 1998, 67: 753-791. 10.1146/annurev.biochem.67.1.753.CrossRefPubMed
10.
go back to reference Kirsch T, Nickel J, Sebald W: BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II. EMBO J. 2000, 19: 3314-3324. 10.1093/emboj/19.13.3314.CrossRefPubMedPubMedCentral Kirsch T, Nickel J, Sebald W: BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II. EMBO J. 2000, 19: 3314-3324. 10.1093/emboj/19.13.3314.CrossRefPubMedPubMedCentral
11.
go back to reference Nickel J, Dryer MK, Kirsch T, Sebald W: The crystal structure of the BMP-2:BMPR-IA complex and the generation of BMP-2 antagonists. J Bone Joint Surg (Am). 2001, 83-A (Suppl 1): 7-14. Nickel J, Dryer MK, Kirsch T, Sebald W: The crystal structure of the BMP-2:BMPR-IA complex and the generation of BMP-2 antagonists. J Bone Joint Surg (Am). 2001, 83-A (Suppl 1): 7-14.
12.
go back to reference Kuberasampath T, Ridge RJ: US Pat. No. 5171574. 1992 Kuberasampath T, Ridge RJ: US Pat. No. 5171574. 1992
13.
go back to reference Rosen V: BMP and BMP inhibitors in bone. Ann N Y Acad Sci. 2006, 1068: 19-25. 10.1196/annals.1346.005.CrossRefPubMed Rosen V: BMP and BMP inhibitors in bone. Ann N Y Acad Sci. 2006, 1068: 19-25. 10.1196/annals.1346.005.CrossRefPubMed
14.
go back to reference Kan L, Hu M, Gomes WA, Kessler JA: Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype. Am J Pathol. 2004, 165: 1107-1115.CrossRefPubMedPubMedCentral Kan L, Hu M, Gomes WA, Kessler JA: Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype. Am J Pathol. 2004, 165: 1107-1115.CrossRefPubMedPubMedCentral
15.
go back to reference Lucotte G, Bathelier C, Mercier G, Gerard N, Lenoir G, Semonin O, Fontaine K: Localization of the gene for fibrodysplasia ossificans progressiva (FOP) to chromosome 17q21-22. Genet Couns. 2000, 11: 329-334.PubMed Lucotte G, Bathelier C, Mercier G, Gerard N, Lenoir G, Semonin O, Fontaine K: Localization of the gene for fibrodysplasia ossificans progressiva (FOP) to chromosome 17q21-22. Genet Couns. 2000, 11: 329-334.PubMed
16.
go back to reference Semonin O, Fontaine K, Daviaud C, Ayuso C, Lucotte G: Identification of three novel mutations of the noggin gene in patients with fibrodysplasia ossificans progressiva. Am J Med Genet. 2001, 102: 314-317. 10.1002/ajmg.1504.CrossRefPubMed Semonin O, Fontaine K, Daviaud C, Ayuso C, Lucotte G: Identification of three novel mutations of the noggin gene in patients with fibrodysplasia ossificans progressiva. Am J Med Genet. 2001, 102: 314-317. 10.1002/ajmg.1504.CrossRefPubMed
17.
go back to reference Tardif G, Hum D, Pelletier JP, Boileau C, Ranger P, Martel-Pelletier J: Differential gene expression and regulation of the bone morphogenetic protein antagonists follistatin and gremlin in normal and osteoarthritic human chondrocytes and synovial fibroblasts. Arthritis Rheum. 2004, 50: 2521-2530. 10.1002/art.20441.CrossRefPubMed Tardif G, Hum D, Pelletier JP, Boileau C, Ranger P, Martel-Pelletier J: Differential gene expression and regulation of the bone morphogenetic protein antagonists follistatin and gremlin in normal and osteoarthritic human chondrocytes and synovial fibroblasts. Arthritis Rheum. 2004, 50: 2521-2530. 10.1002/art.20441.CrossRefPubMed
18.
go back to reference Holleville N, Quilhac A, Bontoux M, Monsoro-Burq AH: BMP signals regulate Dlx5 during early avian skull development. Dev Biol. 2003, 257: 177-189. 10.1016/S0012-1606(03)00059-9.CrossRefPubMed Holleville N, Quilhac A, Bontoux M, Monsoro-Burq AH: BMP signals regulate Dlx5 during early avian skull development. Dev Biol. 2003, 257: 177-189. 10.1016/S0012-1606(03)00059-9.CrossRefPubMed
19.
go back to reference Settle SHJ, Rountree RB, Sinha A, Thacker A, Higgins K, Kingsley DM: Multiple joint and skeletal patterning defects caused by single and double mutations in the mouse Gdf6 and Gdf5 genes. Dev Biol. 2003, 254: 116-130. 10.1016/S0012-1606(02)00022-2.CrossRefPubMed Settle SHJ, Rountree RB, Sinha A, Thacker A, Higgins K, Kingsley DM: Multiple joint and skeletal patterning defects caused by single and double mutations in the mouse Gdf6 and Gdf5 genes. Dev Biol. 2003, 254: 116-130. 10.1016/S0012-1606(02)00022-2.CrossRefPubMed
20.
go back to reference Warren SM, Brunet LJ, Harland RM, Economides AN, Longaker MT: The BMP antagonist Noggin regulates cranial suture fusion. Nature. 2003, 422: 625-629. 10.1038/nature01545.CrossRefPubMed Warren SM, Brunet LJ, Harland RM, Economides AN, Longaker MT: The BMP antagonist Noggin regulates cranial suture fusion. Nature. 2003, 422: 625-629. 10.1038/nature01545.CrossRefPubMed
21.
go back to reference Gosain AK, Recinos RF, Agresti M, Khanna AK: TGF-beta1, FGF-2, and receptor mRNA expression in suture mesenchyme and dura versus underlying brain in fusing and nonfusing mouse cranial sutures. Plast Reconstr Surg. 2004, 113: 1675-1684. 10.1097/01.PRS.0000117362.33347.43.CrossRefPubMed Gosain AK, Recinos RF, Agresti M, Khanna AK: TGF-beta1, FGF-2, and receptor mRNA expression in suture mesenchyme and dura versus underlying brain in fusing and nonfusing mouse cranial sutures. Plast Reconstr Surg. 2004, 113: 1675-1684. 10.1097/01.PRS.0000117362.33347.43.CrossRefPubMed
22.
go back to reference Poisson E, Sciote JJ, Koepsel R, Cooper GM, Opperman LA: Transforming growth factor-beta isoform expression in the perisutural tissues of craniosynostotic rabbits. Cleft Palate Craniofac J. 2004, 41: 392-402. 10.1597/02-140.1.CrossRefPubMed Poisson E, Sciote JJ, Koepsel R, Cooper GM, Opperman LA: Transforming growth factor-beta isoform expression in the perisutural tissues of craniosynostotic rabbits. Cleft Palate Craniofac J. 2004, 41: 392-402. 10.1597/02-140.1.CrossRefPubMed
23.
go back to reference Glaser DL, Economides AN, Wang L, Liu X, Kimble RD, Fandl JP, Wilson JM, Stahl N, Kaplan FS, Shore EM: In vivo somatic cell gene transfer of an engineered Noggin mutein prevents BMP4-induced heterotopic ossification. J Bone Joint Surg Am. 2003, 85-A: 2332-2342.PubMed Glaser DL, Economides AN, Wang L, Liu X, Kimble RD, Fandl JP, Wilson JM, Stahl N, Kaplan FS, Shore EM: In vivo somatic cell gene transfer of an engineered Noggin mutein prevents BMP4-induced heterotopic ossification. J Bone Joint Surg Am. 2003, 85-A: 2332-2342.PubMed
24.
go back to reference Hannallah D, Peng H, Young B, Usas A, Gearhart B, Huard J: Retroviral delivery of Noggin inhibits the formation of heterotopic ossification induced by BMP-4, demineralized bone matrix, and trauma in an animal model. J Bone Joint Surg Am. 2004, 86-A: 80-91.PubMed Hannallah D, Peng H, Young B, Usas A, Gearhart B, Huard J: Retroviral delivery of Noggin inhibits the formation of heterotopic ossification induced by BMP-4, demineralized bone matrix, and trauma in an animal model. J Bone Joint Surg Am. 2004, 86-A: 80-91.PubMed
25.
go back to reference Weber FE, Eyrich G, Gratz KW, Thomas RM, Maly FE, Sailer HF: Disulfide bridge conformers of mature BMP are inhibitors for heterotopic ossification. Biochem Biophys Res Commun. 2001, 286: 554-558. 10.1006/bbrc.2001.5408.CrossRefPubMed Weber FE, Eyrich G, Gratz KW, Thomas RM, Maly FE, Sailer HF: Disulfide bridge conformers of mature BMP are inhibitors for heterotopic ossification. Biochem Biophys Res Commun. 2001, 286: 554-558. 10.1006/bbrc.2001.5408.CrossRefPubMed
26.
go back to reference Weber FE, Schmokel H, Oelgeschlager M, Nickel J, Maly FE, Hortschansky P, Gratz KW: Deletion mutants of BMP folding variants act as BMP antagonists and are efficient inhibitors for heterotopic ossification. J Bone Miner Res. 2003, 18: 2142-2151. 10.1359/jbmr.2003.18.12.2142.CrossRefPubMed Weber FE, Schmokel H, Oelgeschlager M, Nickel J, Maly FE, Hortschansky P, Gratz KW: Deletion mutants of BMP folding variants act as BMP antagonists and are efficient inhibitors for heterotopic ossification. J Bone Miner Res. 2003, 18: 2142-2151. 10.1359/jbmr.2003.18.12.2142.CrossRefPubMed
Metadata
Title
Biological activity of a genetically modified BMP-2 variant with inhibitory activity
Authors
Uwe Klammert
Joachim Nickel
Kristian Würzler
Christoph Klingelhöffer
Walter Sebald
Alexander C Kübler
Tobias Reuther
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Head & Face Medicine / Issue 1/2009
Electronic ISSN: 1746-160X
DOI
https://doi.org/10.1186/1746-160X-5-6

Other articles of this Issue 1/2009

Head & Face Medicine 1/2009 Go to the issue